Oxfordshire Clinical Commissioning Group Formulary

	Oxfordshire Clinical Commissioning Group
	Formulary

Search

Formulary Chapter 13: Skin - Full Chapter

13.10.02

Antifungal preparations

Amorolfine (Loceryl^®)

Restricted

Treatment for superficial onychomycosis (fungal nail infection) in line with SCAN guidelines.

Can be purchased over the counter, in line with Clinical Commissioning Policy 88D.

PrescQIPP: Topical antifungal nail treatment review

Clotrimazole 1%
(skin)

Restricted

Can be purchased over the counter, in line with Clinical Commissioning Policy 88D.

See SCAN guidelines.

Miconazole 2%
(Skin)

Restricted

For cutaneous candidiasis - apply until 10 days after lesions healed. Can be purchased over the counter, in line with Clinical Commissioning Policy 88D.

See SCAN guidelines.

MHRA 2016: Reminder of potential for serious interactions with warfarin

Ketoconazole
(Cream)

Formulary

For continuation following specialist recommendation for seborrhoeic dermatitis and pityriasis versicolor.

Terbinafine 1% cream
(skin)

Restricted

For treatment of fungal / dermatophyte infection of the skin, in line with SCAN guidelines.

Can be purchased over the counter, in line with Clinical Commissioning Policy 88D.

....

Non Formulary Items

Benzoic Acid
(Benzoic acid ointment compound bp (whitfields cream))

Non Formulary

Econazole 1% (Pevaryl^®)
(skin cream)

Non Formulary

Econazole Nitrate 1% (Pevaryl^®)

Non Formulary

Griseofulvin (Grisol AF^®)

Non Formulary

Nystatin
(skin)

Non Formulary

Nystatin as is NOT effective against dermatophytes.

Nystatin with Chlorhexidine cream (Nystaform^®)

Non Formulary

Cream 30g
Nystatin 100,000 units/g with Chlorhexidine Hydrochloride 1%

MHRA alert: Anaphylaxis risk with chlorhexidine

Salicylic Acid (Phytex^®)

Non Formulary

Sulconazole Nitrate (Exelderm^®)

Non Formulary

Tioconazole (Trosyl^®)

Non Formulary

Undecenoates (Monphytol^®)

Non Formulary

Undecenoates (Mycota^®)

Non Formulary

For athletes foot only, available to purchase over the counter in line with Clinical Commissioning Policy 88D.

See SCAN guidelines.

Key

	Notes
	Section Title (top level)
	Section Title (sub level)
	First Choice item
	Non Formulary section
	Restricted Drug
	Unlicensed
	Display tracking information
	Link to adult BNF
	Link to children's BNF
	Link to SPCs
	Scottish Medicines Consortium

	Cytotoxic Drug
	Controlled Drug
	High Cost Medicine
	Cancer Drugs Fund
	NHS England
	Homecare
	CCG

Traffic Light Status Information

Status	Description
	Red: Medicines which should only be prescribed in secondary care by a specialist.
	Amber Continuation: Medicines which should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the GP that the prescribing responsibility has been transferred.
	Amber Shared Care Protocol: Medicines which are appropriate to be initiated and stabilised by a specialist, once stabilised the medicine may be appropriate for responsibility to be transferred from secondary to primary care with the agreement of a GP and a formal ‘shared care’ agreement. The shared care protocol must be approved by the Area Prescribing Committee Oxfordshire (APCO).
	Green: Medicines which are suitable for initiation and ongoing prescribing within primary care.
	Brown: Medicines which should only be prescribed in restricted circumstances.
	Black: Medicines which are not recommended for use because of lack of evidence of clinical effectiveness, cost effectiveness or safety.
	not used